JP7631200B2 - 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ） - Google Patents

放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ） Download PDF

Info

Publication number
JP7631200B2
JP7631200B2 JP2021540019A JP2021540019A JP7631200B2 JP 7631200 B2 JP7631200 B2 JP 7631200B2 JP 2021540019 A JP2021540019 A JP 2021540019A JP 2021540019 A JP2021540019 A JP 2021540019A JP 7631200 B2 JP7631200 B2 JP 7631200B2
Authority
JP
Japan
Prior art keywords
skin
naca
dinaca
formulated
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021540019A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020146666A5 (https=
JP2022518174A5 (https=
JP2022518174A (ja
Inventor
ジー． マイケル ウォール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nacuity Pharmaceuticals Inc
Original Assignee
Nacuity Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nacuity Pharmaceuticals Inc filed Critical Nacuity Pharmaceuticals Inc
Publication of JP2022518174A publication Critical patent/JP2022518174A/ja
Publication of JPWO2020146666A5 publication Critical patent/JPWO2020146666A5/ja
Publication of JP2022518174A5 publication Critical patent/JP2022518174A5/ja
Priority to JP2025017406A priority Critical patent/JP2025069381A/ja
Application granted granted Critical
Publication of JP7631200B2 publication Critical patent/JP7631200B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021540019A 2019-01-11 2020-01-09 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ） Active JP7631200B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025017406A JP2025069381A (ja) 2019-01-11 2025-02-05 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962791422P 2019-01-11 2019-01-11
US62/791,422 2019-01-11
PCT/US2020/012975 WO2020146666A1 (en) 2019-01-11 2020-01-09 N-acetylcysteine amide (naca) and (2r,2r')-3,3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025017406A Division JP2025069381A (ja) 2019-01-11 2025-02-05 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）

Publications (4)

Publication Number Publication Date
JP2022518174A JP2022518174A (ja) 2022-03-14
JPWO2020146666A5 JPWO2020146666A5 (https=) 2023-01-20
JP2022518174A5 JP2022518174A5 (https=) 2023-01-20
JP7631200B2 true JP7631200B2 (ja) 2025-02-18

Family

ID=71521154

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021540019A Active JP7631200B2 (ja) 2019-01-11 2020-01-09 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）
JP2025017406A Pending JP2025069381A (ja) 2019-01-11 2025-02-05 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025017406A Pending JP2025069381A (ja) 2019-01-11 2025-02-05 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）

Country Status (6)

Country Link
US (1) US12458608B2 (https=)
EP (1) EP3908271A4 (https=)
JP (2) JP7631200B2 (https=)
KR (1) KR102745520B1 (https=)
CN (1) CN113573704A (https=)
WO (1) WO2020146666A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472157B2 (en) 2014-11-07 2025-11-18 Nacuity Pharmaceuticals, Inc. Treatment of retinitis pigmentosa with n-acetylcysteine amide
US20190135741A1 (en) 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
EP3908271A4 (en) 2019-01-11 2022-10-26 NaCuity Pharmaceuticals, Inc. N-ACETYLCYSTEINE AMIDE (NACA) AND (2R,2R')-3,3'-DISULFANDIYL BIS-(2-ACETAMIDOPROPANAMIDE) (DINACA) FOR THE PREVENTION AND TREATMENT OF RADIATION DERMATITIS AND SKIN LIGHTENING AND IMPROVEMENT
WO2020146660A1 (en) 2019-01-11 2020-07-16 Nacuity Pharmaceuticals, Inc. N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis
EP3908341A4 (en) 2019-01-11 2022-03-02 NaCuity Pharmaceuticals, Inc. TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA)
AU2021209953B2 (en) * 2020-01-24 2024-08-22 Nacuity Pharmaceuticals, Inc. Prodrug for the treatment of disease and injury of oxidative stress
KR102693441B1 (ko) * 2021-05-26 2024-08-08 경북대학교 산학협력단 시스테인 유도체의 피부 미백 용도
WO2024013711A1 (en) 2022-07-15 2024-01-18 Universidade De Coimbra Topical composition and uses thereof
EP4659758A1 (en) * 2023-01-31 2025-12-10 Mitsubishi Corporation Life Sciences Limited Anti-aging composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005350405A (ja) 2004-06-11 2005-12-22 Shiseido Co Ltd 重合抑制剤および即時型黒化防止用皮膚外用剤
JP2008538586A (ja) 2005-04-21 2008-10-30 グレン エー． ゴールドスタイン， 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド）
JP2013533234A (ja) 2010-06-15 2013-08-22 ヒストセル ソシエダッド リミターダ 抗酸化組成物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252866A (en) 1965-06-28 1966-05-24 Mead Johnson & Co 2-hydrocarbon substituted-amido mercaptopropionamides in hair waving compositions and processes
US6420429B1 (en) 1997-12-23 2002-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds
US5874468A (en) 1996-12-26 1999-02-23 Yissum Brain targeted low molecular weight hydrophobic antioxidant compounds
US20030229141A1 (en) * 1999-01-08 2003-12-11 Yu Ruey J. N-acetyl cysteine and its topical use
US20030027745A1 (en) 2001-06-13 2003-02-06 Repine John E. Diagnostic and prognostic method for evaluating ocular inflammation and oxidative stress and the treatment of the same
BE1014949A3 (fr) 2001-08-14 2004-07-06 Probiox Procede de detection de stress oxydant et trousse pour sa mise en oeuvre.
US20060211628A1 (en) 2002-08-02 2006-09-21 Daphne Atlas Treatment of multiple sclerosis with brain targeted anti oxidant compounds
US7795203B2 (en) 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
CN101232877A (zh) * 2005-04-21 2008-07-30 格伦·A·戈尔茨坦 治疗与氧化应激有关的疾病和病症的n-乙酰半胱氨酸酰胺（nac酰胺）
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
JP4840804B2 (ja) 2006-01-20 2011-12-21 学校法人慶應義塾 酸化ストレスの判定方法
WO2010048716A1 (en) 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US20120150029A1 (en) 2008-12-19 2012-06-14 University Of Miami System and Method for Detection and Monitoring of Ocular Diseases and Disorders using Optical Coherence Tomography
WO2011044230A2 (en) * 2009-10-06 2011-04-14 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions
US20120142550A1 (en) 2010-12-06 2012-06-07 Zehnder James L Vanin 1 as a Peripheral Blood Oxidative Stress Sensor
WO2013138744A1 (en) * 2012-03-16 2013-09-19 M. Alphabet 1, Llc Compositions for the treatment of skin disorders
EP2928562A4 (en) 2012-12-06 2016-06-22 Stealth Peptides Int Inc PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE
US20150328337A1 (en) 2012-12-19 2015-11-19 The Johns Hopkins University Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase
US9763902B2 (en) 2014-03-28 2017-09-19 Nacuity Pharmaceuticals, Inc Method for preparation of N-acetyl cysteine amide
US12472157B2 (en) 2014-11-07 2025-11-18 Nacuity Pharmaceuticals, Inc. Treatment of retinitis pigmentosa with n-acetylcysteine amide
WO2016077467A1 (en) 2014-11-11 2016-05-19 The Johns Hopkins University Biomarkers useful in the treatment of subjects having diseases of the eye
JP7418958B2 (ja) 2016-03-17 2024-01-22 チオジェネシス セラピューティクス， インコーポレイテッド システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療
EP3684756A4 (en) 2017-09-20 2020-10-28 NaCuity Pharmaceuticals, Inc. SYNTHESIS OF N-ACETYLCYSTEIN AMIDE AND ITS DERIVATIVES
JP7208982B2 (ja) 2017-09-20 2023-01-19 チオジェネシス セラピューティクス， インコーポレイテッド システアミン感受性障害の治療方法
WO2019060704A1 (en) 2017-09-22 2019-03-28 University Of Florida Research Foundation DEVICES AND METHODS FOR REDUCTION OF IN VIVO CYSTINE CRYSTALS
US20190135741A1 (en) 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
WO2019097434A1 (en) 2017-11-17 2019-05-23 Mahmood Piraee Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
CN108618993B (zh) * 2018-07-16 2021-07-27 广东格烯生物科技股份有限公司 一种美白组合物及其制备方法和应用
WO2020102810A1 (en) 2018-11-16 2020-05-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Thermoresponsive gel eye drop for ocular delivery of cysteamine
EP3908341A4 (en) 2019-01-11 2022-03-02 NaCuity Pharmaceuticals, Inc. TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA)
WO2020146660A1 (en) 2019-01-11 2020-07-16 Nacuity Pharmaceuticals, Inc. N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis
EP3908271A4 (en) 2019-01-11 2022-10-26 NaCuity Pharmaceuticals, Inc. N-ACETYLCYSTEINE AMIDE (NACA) AND (2R,2R')-3,3'-DISULFANDIYL BIS-(2-ACETAMIDOPROPANAMIDE) (DINACA) FOR THE PREVENTION AND TREATMENT OF RADIATION DERMATITIS AND SKIN LIGHTENING AND IMPROVEMENT

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005350405A (ja) 2004-06-11 2005-12-22 Shiseido Co Ltd 重合抑制剤および即時型黒化防止用皮膚外用剤
JP2008538586A (ja) 2005-04-21 2008-10-30 グレン エー． ゴールドスタイン， 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド）
JP2013533234A (ja) 2010-06-15 2013-08-22 ヒストセル ソシエダッド リミターダ 抗酸化組成物

Also Published As

Publication number Publication date
EP3908271A4 (en) 2022-10-26
US12458608B2 (en) 2025-11-04
JP2025069381A (ja) 2025-04-30
JP2022518174A (ja) 2022-03-14
WO2020146666A9 (en) 2020-09-17
KR20210114460A (ko) 2021-09-23
EP3908271A1 (en) 2021-11-17
WO2020146666A1 (en) 2020-07-16
KR102745520B1 (ko) 2024-12-23
US20220105056A1 (en) 2022-04-07
CN113573704A (zh) 2021-10-29

Similar Documents

Publication Publication Date Title
JP7631200B2 (ja) 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）
AU2021225263B2 (en) Treatment of retinitis pigmentosa with n-acetylcysteine amide
EP3908341A1 (en) Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylicysteine amide (naca) or 2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca)
US20210228509A1 (en) Prodrug for the treatment of disease and injury of oxidative stress
US20260014102A1 (en) Treatment of retinitis pigmentosa and retinitis pigmentosa associated with usher syndrome with n-acetylcysteine amide
US20230381120A1 (en) Treatment of Age-Related Macular Degeneration, Glaucoma, and Diabetic Retinopathy with N-Acetylcysteine Amide (NACA) or (2R,2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide)(DiNACA)
US20220304955A1 (en) Treatment of ferroptosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250205

R150 Certificate of patent or registration of utility model

Ref document number: 7631200

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150